Sun Pharma Advanced Research Co Ltd

The key equity indices ended with substantial losses today, extending their decline for third consecutive trading session, amid mixed economic signals and NSE's F&O contract expiry. Investors will keep an eye on upcoming IPO activity, PMI data and the RBI's monetary policy meeting scheduled later this week. The Nifty closed below the 26,050 mark. Barring pharma all the sectoral indices on the NSE were traded in red with private bank, consumer durables and oil & gas shares declining the most. As per provisional closing data, the barometer index, the S&P BSE Sensex declined 503.63 points or 0.59% to 85,138.27. The Nifty 50 index lost 143.55 points or 0.55% to 26,032.20. Over the last three sessions, the Nifty slipped 0.70%, while the Sensex fell 0.68%. In the broader market, the S&P BSE Mid-Cap index shed 0.19% and the S&P BSE Small-Cap index rose 0.05%. The market breadth was negative. On the BSE, 1,847 shares rose and 2,400 shares fell. A total of 210 shares were unchanged. The NSE's India VIX, a gauge of the market's expectation of volatility over the near term, fell 3.41% to 11.23. Economy: India's IIP growth rate for the month of October 2025 is 0.4%, compared with 4.0% in the month of September 2025. The said decline is 14-month low indicating a sharp slowdown in the economy. India's current account deficit moderated to $12.3 billion (1.3% of GDP) in Q2:2025-26 from $ 20.8 billion (2.2% of GDP) in Q2:2024-25, the RBI said on Monday. Buzzing Index: The Nifty Private Bank index declined 0.69% to 28,558.75. The index fell 0.81% for third consecutive trading session. RBL Bank (down 1.48%), ICICI Bank (down 1.29%), Axis Bank (down 1.19%), HDFC Bank (down 1.1%) and Kotak Mahindra Bank (down 0.27%), Bandhan Bank (down 0.2%) declined. Stocks in Spotlight: Sun Pharma Advanced Research Company (SPARC) was locked in 20% upper circuit after the company announced that the U.S. District Court has granted summary judgement in favour of SPARC for Sezaby PRV. In a regulatory filing made during market hours today, the company stated that the U.S. District Court for the District of Columbia granted summary judgment in favour of SPARC in the matter of issuance of priority review voucher (PRV) associated with the approval of Sezaby. Mini Diamonds India surged 19.95% after the company announced that it has bagged an export order worth $1.50 million (approximately Rs 13.5 crore) from Hong Kong'based Jewellery Trendz. Adani Ports and Special Economic Zone (APSEZ) slipped 0.73%. The company reported handling 41 MMT of cargo in November 2025, marking a 14% year-on-year (YoY) increase, driven by strong growth in containers (20% YoY) and dry cargo (10% YoY). Hero MotoCorp shed 0.27%. The company has recorded 31% rise in total two-wheeler sales in November 2025, selling 604,490 units during the month as compared with 459,805 units dispatched in the same period last year. NMDC added 0.99% after the company reported an 11.09% rise in iron ore production in November 2025 to 5.01 million tonnes (MT), compared to 4.51 MT recorded in the same month of the previous year. GHV Infra Projects declined 2.12%. The company announced that it has secured an order worth Rs 109 crore from GHV (India) for the execution of civil, MEP, and finishing work for the buildings in Jamshedpur, Jharkhand. Force Motors slipped 1.99%. The company's total sales climbed 52.94% to 2,883 units in November 2025 compared with 1,885 units sold in November 2024. Bharat Dynamics shed 0.56%. The company has received orders worth Rs 2,462 crore from Indian Army. Majors orders received include ATGMs and SAM (Emergency Procurement). Websol Energy System jumped 6.46% after the company announced that it has signed a memorandum of understanding (MoU) with Linton, a global leader in PV ingot and wafer equipment technology. As part of the collaboration, Websol plans to acquire PV ingot and wafer manufacturing equipment from Linton. Linton will also provide technical expertise, training, and skills development to Websol's team to ensure optimal operation of the equipment and related processes. Global Markets: European market advanced on Tuesday as investors awaited for Spanish and Italian unemployment figures. Euro zone inflation stood at 2.2% in November, marking a slight rise from the previous month, flash data from data agency Eurostat showed Tuesday. The latest consumer price index reading is just a shade above the European Central Bank's 2% target. Asian market ended mixed, despite growing expectations of a Federal Reserve rate cut next week, while Japanese stocks struggled amid signals the Bank of Japan may raise interest rates. Shares of South Korean auto companies rose Tuesday after U.S. Secretary of Commerce Howard Lutnick confirmed that lower U.S. auto tariffs of 15% on South Korea would retrospectively come into effect, starting Nov. 1. We are also removing tariffs on airplane parts and will 'un-stack' Korea's reciprocal rate to match Japan and the EU,' Lutnick said, according to an X post by the U.S. Department of Commerce. South Korea's headline inflation in November rose 2.4% year on year, according to government data Tuesday. Core inflation, which strips out prices of fresh food and energy, rose 2% from a year earlier. The latest figure is unchanged from October's inflation rate, supporting the case for the central bank to keep interest rates on hold. The Bank of Korea had kept rates unchanged at 2.5% for a fourth straight meeting last Thursday. U.S. equity futures were little changed in early Asian hours after all three key benchmarks snapped five-day gain streaks. Overnight, the S&P 500 lost 0.53% to end at 6,812.63, while the Nasdaq Composite shed 0.38% to finish at 23,275.92. The Dow Jones Industrial Average pulled back by 427.09 points, or 0.9%, to settle at 47,289.33.Powered by Capital Market - Live

In a regulatory filing made during market hours today, the company stated that the U.S. District Court for the District of Columbia granted summary judgment in favour of SPARC in the matter of issuance of priority review voucher (PRV) associated with the approval of Sezaby. The Court granted SPARC's motion for summary judgment and held that 'FDA's withholding of the PRV was contrary to law because no drug product containing phenobarbital sodium was 'previously approved' as that term is used in the statute' and allowed 60 days to appeal against the motion. Anil Raghavan, CEO, SPARC, said: 'We are pleased with the ruling issued today by the U.S. District Court, as it validates SPARC's long held position on this matter.' SEZABY is a benzyl alcohol and propylene glycol free formulation of phenobarbital sodium powder for injection. It was approved by the US FDA for the treatment of neonatal seizures. Sun Pharma Advanced Research Company is a clinical stage bio-pharmaceutical company focused on continuously improving standards of care for patients globally, through innovation in therapeutics and delivery. The company had reported a consolidated net loss of Rs 75.85 crore in the quarter ended September 2025 as against net loss of Rs 107.33 crore during the previous quarter ended September 2024. Sales declined 38.88% to Rs 7.86 crore in Q2 FY26 over Q2 FY25. Powered by Capital Market - Live

Net Loss of Sun Pharma Advanced Research Company reported to Rs 75.85 crore in the quarter ended September 2025 as against net loss of Rs 107.33 crore during the previous quarter ended September 2024. Sales declined 38.88% to Rs 7.86 crore in the quarter ended September 2025 as against Rs 12.86 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales7.8612.86 -39 OPM %-836.13-800.23 - PBDT-73.23-104.01 30 PBT-75.79-107.17 29 NP-75.85-107.33 29 Powered by Capital Market - Live

Sun Pharma Advanced Research Company will hold a meeting of the Board of Directors of the Company on 10 November 2025.Powered by Capital Market - Live

Net Loss of Sun Pharma Advanced Research Company reported to Rs 51.87 crore in the quarter ended June 2025 as against net loss of Rs 95.90 crore during the previous quarter ended June 2024. Sales declined 42.65% to Rs 9.64 crore in the quarter ended June 2025 as against Rs 16.81 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales9.6416.81 -43 OPM %-540.25-555.38 - PBDT-49.13-92.36 47 PBT-51.81-95.50 46 NP-51.87-95.90 46 Powered by Capital Market - Live

Sun Pharma Advanced Research Company will hold a meeting of the Board of Directors of the Company on 4 August 2025.Powered by Capital Market - Live

Sun Pharma Advanced Research Company announced that the 20th Annual General Meeting(AGM) of the company will be held on 12 August 2025.Powered by Capital Market - Live

In a regulatory filing, SPARC said that its partner, Sun Pharmaceutical Industries (SPIL), reported top-line results from Phase 2 studies of Vibozilimod (SCD-044), a drug candidate aimed at treating moderate-to-severe psoriasis and atopic dermatitis. Both trials failed to meet their primary endpoints: a 75% improvement in the Psoriasis Area and Severity Index (PASI75) and Eczema Area and Severity Index (EASI75), respectively, by Week 16. Following the setback, SPARC and SPIL stated they would assess the appropriate next steps for the development of Vibozilimod. SPARC is a clinical stage bio-pharmaceutical company focused on continuously improving standards of care for patients globally, through innovation in therapeutics and delivery. On a consolidated basis, SPARC reported net loss of Rs 59.77 crore in Q4 March 2025 as against net loss of Rs 105.79 crore in Q4 March 2024. Net sales rose 64.19% year-on-year to Rs 27.19 crore in Q4 March 2025. Powered by Capital Market - Live

Aditya Birla Fashion & Retail Ltd, Fusion Finance Ltd Partly Paidup, Alivus Life Sciences Ltd and Indo Count Industries Ltd are among the other losers in the BSE's 'A' group today, 04 June 2025.Sun Pharma Advanced Research Company Ltd lost 18.76% to Rs 158.9 at 14:46 IST.The stock was the biggest loser in the BSE's 'A' group.On the BSE, 9.45 lakh shares were traded on the counter so far as against the average daily volumes of 94359 shares in the past one month.Aditya Birla Fashion & Retail Ltd crashed 10.33% to Rs 77.1. The stock was the second biggest loser in 'A' group.On the BSE, 437.77 lakh shares were traded on the counter so far as against the average daily volumes of 4.25 lakh shares in the past one month.Fusion Finance Ltd Partly Paidup tumbled 3.89% to Rs 100.05. The stock was the third biggest loser in 'A' group.On the BSE, 985 shares were traded on the counter so far as against the average daily volumes of 10093 shares in the past one month.Alivus Life Sciences Ltd dropped 3.48% to Rs 1024. The stock was the fourth biggest loser in 'A' group.On the BSE, 2773 shares were traded on the counter so far as against the average daily volumes of 5155 shares in the past one month.Indo Count Industries Ltd fell 3.43% to Rs 271.3. The stock was the fifth biggest loser in 'A' group.On the BSE, 16635 shares were traded on the counter so far as against the average daily volumes of 54599 shares in the past one month.Powered by Capital Market - Live

Net Loss of Sun Pharma Advanced Research Company reported to Rs 59.77 crore in the quarter ended March 2025 as against net loss of Rs 105.79 crore during the previous quarter ended March 2024. Sales rose 64.19% to Rs 27.19 crore in the quarter ended March 2025 as against Rs 16.56 crore during the previous quarter ended March 2024. For the full year,net loss reported to Rs 342.51 crore in the year ended March 2025 as against net loss of Rs 387.21 crore during the previous year ended March 2024. Sales declined 5.00% to Rs 71.77 crore in the year ended March 2025 as against Rs 75.55 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales27.1916.56 64 71.7775.55 -5 OPM %-195.59-639.07 --450.24-532.23 - PBDT-57.72-102.34 44 -330.39-374.32 12 PBT-60.67-105.41 42 -342.78-386.83 11 NP-59.77-105.79 44 -342.51-387.21 12 Powered by Capital Market - Live